Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.
Allelic inactivation
Myeloid neoplasia
Next-generation sequencing
Single-cell DNA sequencing
TP53 mutations
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
03 08 2023
03 08 2023
Historique:
received:
05
03
2023
accepted:
14
07
2023
medline:
7
8
2023
pubmed:
4
8
2023
entrez:
3
8
2023
Statut:
epublish
Résumé
TP53 mutations (TP53 We have collected clinical and molecular data of 7400 patients with myeloid neoplasms and applied a novel model by identifying an optimal VAF cutoff using a statistically robust strategy of sampling-based regression on survival data to accurately classify the TP53 allelic configuration and assess prognosis more precisely. Overall, TP53 Our novel approach more accurately resolves TP53 genomic configuration and uncovers genetic mosaicism for the use in the clinical setting to improve prognostic evaluation.
Sections du résumé
BACKGROUND
TP53 mutations (TP53
METHODS
We have collected clinical and molecular data of 7400 patients with myeloid neoplasms and applied a novel model by identifying an optimal VAF cutoff using a statistically robust strategy of sampling-based regression on survival data to accurately classify the TP53 allelic configuration and assess prognosis more precisely.
RESULTS
Overall, TP53
CONCLUSION
Our novel approach more accurately resolves TP53 genomic configuration and uncovers genetic mosaicism for the use in the clinical setting to improve prognostic evaluation.
Identifiants
pubmed: 37537667
doi: 10.1186/s13045-023-01480-y
pii: 10.1186/s13045-023-01480-y
pmc: PMC10401750
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
TP53 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL118281
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL123904
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL132071
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135795
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Blood. 2022 Apr 14;139(15):2347-2354
pubmed: 35108372
Leukemia. 2007 Sep;21(9):2058-61
pubmed: 17525728
Blood. 2013 Dec 12;122(25):4021-34
pubmed: 24136165
Leukemia. 2010 Jan;24(1):216-9
pubmed: 19759556
Nat Genet. 2017 Feb;49(2):204-212
pubmed: 27992414
Genes Chromosomes Cancer. 2003 Dec;38(4):329
pubmed: 14566852
J Clin Oncol. 2013 Jul 1;31(19):2428-36
pubmed: 23690417
Haematologica. 2017 Sep;102(9):1502-1510
pubmed: 28642303
Cold Spring Harb Perspect Med. 2016 Dec 1;6(12):
pubmed: 27663983
Science. 2019 Aug 9;365(6453):599-604
pubmed: 31395785
N Engl J Med. 2011 Jun 30;364(26):2496-506
pubmed: 21714648
Leukemia. 2014 Feb;28(2):241-7
pubmed: 24220272
Nat Commun. 2019 Nov 26;10(1):5386
pubmed: 31772163
Nat Med. 2020 Oct;26(10):1549-1556
pubmed: 32747829
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897
J Clin Oncol. 2021 Apr 10;39(11):1223-1233
pubmed: 33539200
Cancer Immunol Immunother. 2019 Dec;68(12):1971-1978
pubmed: 31650199
Nat Commun. 2019 Dec 11;10(1):5649
pubmed: 31827082
Am J Hematol. 2018 Jan;93(1):65-73
pubmed: 29023992
Nature. 2018 Oct;562(7728):526-531
pubmed: 30333627
Adv Cancer Res. 2000;77:81-137
pubmed: 10549356
Br J Haematol. 2016 Nov;175(3):419-426
pubmed: 27447873
Leuk Res. 2018 May 31;70:97-99
pubmed: 29908419
Cold Spring Harb Perspect Biol. 2010 Jan;2(1):a001008
pubmed: 20182602
Leukemia. 2019 Jul;33(7):1747-1758
pubmed: 30635634
Mod Pathol. 2015 May;28(5):706-14
pubmed: 25412851
Nat Med. 2020 Dec;26(12):1852-1858
pubmed: 33106665
Blood Cancer J. 2016 Jan 15;6:e385
pubmed: 26771811
Blood. 2009 Dec 17;114(26):5307-14
pubmed: 19850740
Blood. 2020 Oct 15;136(16):1851-1862
pubmed: 32573691